Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron ...

The findings, published in The Lancet Respiratory Medicine, suggest that dupilumab, when used alongside standard triple ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic ...

24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma ...

Sanofi to showcases leadership and breadth of scientific innovation in chronic inflammatory respiratory conditions at ATS conference: Paris Saturday, May 3, 2025, 16:00 Hrs [IST] ...

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment options CAN10 ...

Patients with early-onset atopic dermatitis, especially those with severe atopic dermatitis, are more likely to develop pediatric uveitis.